Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Mechanobiology of Aplysia neurons

MAPNE

Memory loss is a central symptom in different diseases such as Alzheimer’s disease, and represents a significant social and economic burden for a large percentage of European citizens. Neuronal cell adhesion molecules belonging to the immunoglobulin superfamily (IgCAMs) are known to be involved in brain development processes, and also contribute to...

Funding Programme
Start Date
End Date
Total Funding
€ 178 374
European Countries Involved

Memory loss in Alzheimer disease: underlying mechanisms and therapeutic targets

MEMOSAD

MEMOSAD aims at defining the molecular mechanisms of Abeta- and Tau-induced synaptotoxicity and at developing disease-modifying therapeutics for the prevention of memory loss in Alzheimer disease (AD). Insoluble aggregates of the two proteins provide the pathological hallmarks of this incurable brain disorder. Early stage AD is characterized by a...

Funding Programme
Start Date
End Date
Total Funding
€ 4 023 080
European Countries Involved

MiCrovasculaR rarefaction in vascUlar Cognitive Impairement and heArt faiLure

CRUCIAL

Vascular dementia and heart failure represent major health burden to morbidity, mortality and quality of life. Comorbidities (hypertension, aging, diabetes, etc.) affect all organs, but the brain and heart are especially sensitive to these chronic stresses resulting in cognitive impairment (a mental disorder) and heart failure (a non-mental...

Funding Programme
Start Date
End Date
Total Funding
€ 6 000 000
European Countries Involved

Neurobiological Mechanisms of Memory Loss in Alzheimer's Disease

MEMOLOAD

The MEMOLOAD project will focus on the molecular and biological mechanisms underlying memory loss that occurs in Alzheimer’s disease, the leading cause of dementia and an enormous medical, social and economic challenge to Europe. Several lines of evidence point to accumulation of beta-amyloid peptide (Aß) in the brain as the key pathologic event in...

Funding Programme
Start Date
End Date
Total Funding
€ 3 928 486
European Countries Involved

Role of Aβ Specific Regulatory T cells in harnessing cerebral Aβ clearance in Alzheimer’s Disease

TREGinAD

With populations ageing, Alzheimer’s disease (AD), for which there is still no cure, has become a major public health problem in Europe. This is partly due to the neglect of the role of the immune responses to the build-up of cerebral Aβ-the pathogenic agent triggering AD. Clinical trials for vaccines aimed at reducing cerebral Aβ were accompanied...

Funding Programme
Start Date
End Date
Total Funding
€ 187 866
European Countries Involved

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

SMASH-HCM

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular...

Funding Programme
Start Date
End Date
Total Funding
€ 8 546 366
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

The effects of an extensive exercise program on the progression of mild cognitive impairment (MCI)

NEUROEXERCICE

Epidemiological studies have shown that leisure-time physical activity at midlife is associated with a decreased risk of dementia later in life. Although initial studies indicate enhanced behavioural performance in dementia patients after three months of exercise, little is known about the effect of an extensive, controlled and regular exercise...

Funding Programme
Start Date
End Date
Total Funding
€ 1 395 100
European Countries Involved

The use of computational techniques to Improve compliance to reminders within smart environments

REMIND

The aim of this Project is to create an International and Intersectoral network to facilitate the exchange of staff to progress developments in reminding technologies for persons with dementia which can be deployed in smart environments. The focus will be on developing staff and partner skills in the areas of user centered design and behavioral...

Funding Programme
Start Date
End Date
Total Funding
€ 1 084 500
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).